AcquisitionsMay 15, 2026, 09:21 AM
Embecta Completes Owen Mumford Acquisition for 100M Upfront
AI Summary
Embecta Corp. announced the completion of its previously announced acquisition of Owen Mumford Holdings Limited, a UK-based innovator and manufacturer of medical devices and drug-delivery technologies. The transaction involved an upfront cash payment of 100 million, with potential additional payments of up to 50 million based on the achievement of commercial milestones related to Aidaptus auto-injector sales. This acquisition is expected to accelerate Embecta's strategic transformation, providing a differentiated drug-delivery platform and expanding its chronic care device portfolio.
Key Highlights
- Embecta completed the acquisition of Owen Mumford Holdings Limited.
- The transaction involved an upfront cash payment of 100 million.
- Up to an additional 50 million will be paid based on Aidaptus sales through June 30, 2029.
- The acquisition accelerates Embecta's strategic transformation into a broad-based medical supplies company.
- It provides a differentiated drug-delivery platform, including the Aidaptus next-generation auto-injector.
- Financial statements and pro forma information will be filed by amendment within 71 days.
Price Impact
More from EMBC